BACKGROUND: The related T(H)2 cytokines IL-4 and IL-13 are produced during allergic responses, signal through receptors that contain IL-4 receptor (IL-4R) alpha, and promote allergic inflammation by activating signal transducer and activator of transcription 6. IL-4 promotes T(H)2 response induction, and IL-13 is necessary and sufficient to induce airways hyperresponsiveness (AHR) and goblet cell hyperplasia in some mouse models of asthma. The nonredundant role of IL-13 could reflect unique IL-13 activation of a signaling pathway, inhibitory effects induced by IL-4 but not IL-13, or greater production-potency of IL-13 than IL-4. OBJECTIVES: We sought to distinguish among these possibilities by determining whether IL-4 inhalation can induce acute allergic airways disease in the absence of IL-13. METHODS: Mice were inoculated intratracheally with IL-13 or a long-acting formulation of IL-4. Responses of IL-13-deficient and IL-13-sufficient mice were compared, as were responses in mice treated with a potent IL-13 antagonist, anti-IL-4Ralpha antibody, or control reagents. RESULTS: IL-4 inhalation stimulated bronchoalveolar lavage fluid eosinophilia, AHR, and goblet cell hyperplasia. These responses were similar in IL-13-deficient and IL-13-sufficient mice and were not inhibited by an IL-13 antagonist but were blocked by anti-IL-4Ralpha antibody. CONCLUSION: IL-4 can induce IL-13-independent AHR and goblet cell hyperplasia. Thus the greater role for IL-13 than IL-4 in the induction of these acute allergy-related changes reflects increased production, potency, or both of IL-13 relative to IL-4 rather than a unique IL-13-signaling pathway or a suppressive effect of IL-4. CLINICAL IMPLICATIONS: Dual IL-4/IL-13 inhibition might be more effective than selective IL-13 inhibition at suppressing allergic inflammation in some circumstances.
BACKGROUND: The related T(H)2 cytokines IL-4 and IL-13 are produced during allergic responses, signal through receptors that contain IL-4 receptor (IL-4R) alpha, and promote allergic inflammation by activating signal transducer and activator of transcription 6. IL-4 promotes T(H)2 response induction, and IL-13 is necessary and sufficient to induce airways hyperresponsiveness (AHR) and goblet cell hyperplasia in some mouse models of asthma. The nonredundant role of IL-13 could reflect unique IL-13 activation of a signaling pathway, inhibitory effects induced by IL-4 but not IL-13, or greater production-potency of IL-13 than IL-4. OBJECTIVES: We sought to distinguish among these possibilities by determining whether IL-4 inhalation can induce acute allergic airways disease in the absence of IL-13. METHODS:Mice were inoculated intratracheally with IL-13 or a long-acting formulation of IL-4. Responses of IL-13-deficient and IL-13-sufficient mice were compared, as were responses in mice treated with a potent IL-13 antagonist, anti-IL-4Ralpha antibody, or control reagents. RESULTS:IL-4 inhalation stimulated bronchoalveolar lavage fluid eosinophilia, AHR, and goblet cell hyperplasia. These responses were similar in IL-13-deficient and IL-13-sufficient mice and were not inhibited by an IL-13 antagonist but were blocked by anti-IL-4Ralpha antibody. CONCLUSION:IL-4 can induce IL-13-independent AHR and goblet cell hyperplasia. Thus the greater role for IL-13 than IL-4 in the induction of these acute allergy-related changes reflects increased production, potency, or both of IL-13 relative to IL-4 rather than a unique IL-13-signaling pathway or a suppressive effect of IL-4. CLINICAL IMPLICATIONS: Dual IL-4/IL-13 inhibition might be more effective than selective IL-13 inhibition at suppressing allergic inflammation in some circumstances.
Authors: Daniel E Dulek; Dawn C Newcomb; Kasia Goleniewska; Jaqueline Cephus; Weisong Zhou; Sara Reiss; Shinji Toki; Fei Ye; Rinat Zaynagetdinov; Taylor P Sherrill; Timothy S Blackwell; Martin L Moore; Kelli L Boyd; Jay K Kolls; R Stokes Peebles Journal: Infect Immun Date: 2014-06-23 Impact factor: 3.441
Authors: Fred D Finkelman; Simon P Hogan; Gurjit K Khurana Hershey; Marc E Rothenberg; Marsha Wills-Karp Journal: J Immunol Date: 2010-02-15 Impact factor: 5.422
Authors: Christopher G McKnight; Joseph A Jude; Zhenqi Zhu; Reynold A Panettieri; Fred D Finkelman Journal: Am J Respir Cell Mol Biol Date: 2017-12 Impact factor: 6.914
Authors: Ariel Munitz; Eric T Cole; Danielle Karo-Atar; Fred D Finkelman; Marc E Rothenberg Journal: Am J Respir Cell Mol Biol Date: 2012-01-12 Impact factor: 6.914
Authors: Carine Bouffi; Mark Rochman; Christopher B Zust; Emily M Stucke; Andrey Kartashov; Patricia C Fulkerson; Artem Barski; Marc E Rothenberg Journal: J Immunol Date: 2013-09-16 Impact factor: 5.422
Authors: Guillermina A Melendi; Scott J Hoffman; Ruth A Karron; Pablo M Irusta; Federico R Laham; Alison Humbles; Brian Schofield; Chien-Hsiung Pan; Richard Rabold; Bhagvanji Thumar; Adeep Thumar; Norma P Gerard; Wayne Mitzner; Scott R Barnum; Craig Gerard; Steven R Kleeberger; Fernando P Polack Journal: J Virol Date: 2006-11-01 Impact factor: 5.103
Authors: Steven K Juhn; Min-Kyo Jung; Mark D Hoffman; Brian R Drew; Diego A Preciado; Nicholas J Sausen; Timothy T K Jung; Bo Hyung Kim; Sang-Yoo Park; Jizhen Lin; Frank G Ondrey; David R Mains; Tina Huang Journal: Clin Exp Otorhinolaryngol Date: 2008-09-30 Impact factor: 3.372
Authors: Jie Lan; Leslie Ribeiro; Isabel Mandeville; Katia Nadeau; Tim Bao; Salomon Cornejo; Neil B Sweezey; Feige Kaplan Journal: Respir Res Date: 2009-09-21